Market Place
Sourcing Support
Certa Therapeutics Names GPR68 Inhibitor Asengeprast
16 Sep 2024 //
GLOBENEWSWIRE
Certa`s FT011 Gets EU Orphan Status For Systemic Sclerosis Treatment
22 Jul 2024 //
GLOBENEWSWIRE
Brandon Capital raises $180M for Australia, New Zealand biotechs
04 Jun 2024 //
FIERCE BIOTECH
Certa FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis
19 Feb 2024 //
GLOBENEWSWIRE
Certa presents data from a Phase 2 clinical study highlighting benefit of FT011
15 Nov 2023 //
GLOBENEWSWIRE
Certa Therapeutics` FT011 Granted US FDA Orphan Drug Designation
23 Oct 2023 //
PR NEWSWIRE
Australian biotech touts a positive mid-stage data readout — with old Shire drug
07 Feb 2023 //
ENDPTS
Ex-Shire drug improves outcomes in phase 2 autoimmune trial
06 Feb 2023 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.